Interestingly, nivolumab treatment was initiated after priming the tumor microenvironment with either irradiation or chemotherapy, resulting in a promising response rate that appeared higher than expected based on previous PD-1/PD-L1 blockade monotherapy studies in unselected TNBC. This evidence concerns the gene CD274 and neoplasm.